FREQUENTLY ASKED QUESTIONS

MIPS 410: Psoriasis: Clinical Response to Systemic Medications FAQs

Is this measure reportable via claims?

NΙο

Does this measure need to be reported every time the patient comes into the office?

No, this measure only needs to be reported once per performance period.

Why is a static benchmark used rather than PASI 75 or PASI 90?

Both instruments used in the measure are different. Part of the measure is evaluating whether the score has improved. In order to measure if the score improved, a static score is not used.

What medications are applicable to the measure?

Applicable medications are on the measure specification. You can find the specification here: https://www.aad.org/practicecenter/quality/quality-measures/mips-measures/410. You can also find a list of medications on this page if you download the documentation tip sheet.

Can I report on this measure if I did not prescribe the medication?

No, only the provider who prescribes the medication is eligible for this measure.

Is this measure reportable for other kinds of psoriasis?

No, this measure is only reportable for psoriasis vulgaris (plaque psoriasis).

Where are the assessment tools located?

Assessment tools are located in the table below.

Physician global assessment (PGA)	http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4361b1-02-CENTOCOR.pdf Choice of assessment located in appendix B or C.
Body surface area (BSA)	https://www.psoriasis.com/psoriasis-severity http://www.miniwebtool.com/bsa-calculator/
Psoriasis area and severity index (PASI)	http://www.bad.org.uk/shared/get-file.ashx?id=1654&itemtype=document https://www.humanservices.gov.au/health-professionals/forms/pb115 http://www.dermnetnz.org/topics/pasi-score/
Dermatology life quality index (DLQI)	http://www.bad.org.uk/shared/get-file.ashx?itemtype=document&id=1653

